ZG006 not checked
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Small Cell Lung Cancer (5 trials), Neuroendocrine Carcinoma (4 trials), Small-cell Lung Cancer, Neuroendocrine Prostate Cancer, Neuroendocrine Cancer, Solid Tumor, Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Main trialPhase 3
- “This Phase III, multicenter, randomized, open-label, controlled study is designed to assess the efficacy and safety of ZG006 versus investigator-selected chemotherapy in participants with DLL3-positive advanced neuroendocrine carcinoma who have received prior systemic therapy.”In the company’s words, NCT07595913 on ClinicalTrials.gov
Other drugs for Small Cell Lung Cancer
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- MHB088CQilu Pharmaceutical · Phase 3
Coming up9
- DecPhase 1 trial completes · ClinicalTrials.gov
- Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Sep 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 15 Sep 2028Phase 1 trial completes · ClinicalTrials.gov
- Oct 2028Phase 3 trial completes · ClinicalTrials.gov
- Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Jun 2028 | A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma | |
| Phase 3Recruiting | Oct 2028 | Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer | |
| Phase 2Not yet recruiting | Dec 2027 | Study of ZG006 in Participants With Neuroendocrine Prostate Cancer | |
| Phase 1/2Recruiting | May 2026 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. | |
| Phase 1/2Recruiting | Sep 2026 | Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | |
| Phase 1/2Recruiting | Apr 2027 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer | |
| Phase 1/2Recruiting | Sep 2027 | ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | |
| Phase 1/2Recruiting | Dec 2028 | Study of ZGGS34 in Participants With Advanced Solid Tumors | |
| Phase 1Recruiting | Dec 2026 | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | |
| Phase 1Not yet recruiting | 15 Sep 2028 | A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC | |
| Phase 1Recruiting | Dec 2028 | Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026